Novo Nordisk Takes Lilly to Court Over GLP-1 Ad Claims as Market Share Battle Intensifies
Published on 07/26/2026 at 03:51 | Redaktion boerse-global.de
Novo Nordisk has escalated its legal confrontation with Eli Lilly, filing for a preliminary injunction in a New Jersey federal court on July 24 to halt what it calls misleading advertising for Lilly’s Zepbound and Mounjaro. The move marks a sharp shift in strategy for the Danish drugmaker, which now aims to use the courts to counter a rival that has seized a commanding lead in the obesity market.
At the heart of the dispute is a comparison Lilly has been running in its promotional materials, based on the SURMOUNT-5 head-to-head study. Novo Nordisk argues that the ads pit high doses of Lilly’s drugs against outdated or lower doses of Wegovy, deliberately omitting the 7.2-milligram version that won FDA approval in March. The company claims this creates a false impression of Wegovy’s efficacy. Lilly has pushed back, insisting its communications are truthful and transparent.
The legal timeline is tight. A hearing on the injunction request is scheduled for August 17, just days after Novo Nordisk releases its second-quarter earnings on August 5. Analysts will be watching both events closely for clues on how the competitive dynamics are shifting.
The Market Reality Behind the Courtroom Drama
The numbers tell a stark story. Novo Nordisk now holds 42 percent of the obesity market, while Lilly commands 59.5 percent. That gap has widened as Lilly’s portfolio has expanded rapidly — most notably with Foundayo, an oral pill that the FDA approved in a record 50 days, intensifying what has become a full-blown “pill war” over patient convenience.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Novo Nordisk does have a counterpunch of its own. The oral version of Wegovy has already generated more than 3 million prescriptions in the U.S., accounting for roughly 30 percent of all Wegovy scripts. That shift toward oral formulations is driving meaningful growth, and the newly approved higher dose gives doctors a clinical argument to counter Lilly’s weight-loss claims.
Institutional investors are taking note. Renaissance Technologies boosted its Novo Nordisk position by 6.7 percent in the first quarter, while Arrowstreet Capital initiated a new stake.
Stock Price Caught Between Recovery and Resistance
The shares closed the week at €42.85 on Friday, up 1.19 percent on the day. That leaves the stock 41.65 percent above its 52-week low from March, suggesting a solid floor has formed since the spring trough. But the recovery remains incomplete: the stock is still down 2.67 percent year-to-date and 29.70 percent below its July 2025 peak of €60.95.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Technical levels offer some guideposts. The shares are trading above their 200-day moving average of €40.38, a positive signal for the recovery trend. If the injunction is granted after the August 17 hearing, analysts see a realistic chance for the stock to stabilize above €43. A ruling in Lilly’s favor, or signs that Foundayo is eroding Wegovy’s prescription growth, could send the stock back toward its 50-day average of €40.36.
The annualized 30-day volatility of 26.83 percent underscores how much uncertainty is priced in. Between the court date, the earnings release, and the relentless competitive pressure, Novo Nordisk’s next few weeks will test whether its legal gambit can buy the time needed to close the gap with Lilly.
Ad
Novo Nordisk Stock: New Analysis - 26 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
